Cancer

Title
Study of an Investigational Medication in Individuals with Melanoma.
Trial Number
203800092111
Number of Participants
1,000
Principal Investigator

Joseph Clark

M.D.
Hematology/Oncology
Professor
Eligibility

Participants must be 18 years of age or older. All individuals must have disease that is completely surgically resected to be eligible. Participants must have been surgically rendered free of disease with negative margins on resected specimen. Individuals rendered free of disease by non-surgical means are not eligible.
All participants must have disease-free status documented by a complete physical examination and imaging studies within four weeks prior to randomization. Imaging studies must include a total body PET-CT scan (with or without brain) and brain MRI or CT (if MRI is contraindicated). If PET-CT cannot be done, CT of neck, chest, abdomen and pelvis should be done.

Purpose

The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better.

Enrollment

(708) 327-3221

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.